(E/Z) -Zotiraciclib

• Description:

  (E/Z) -Zotiraciclib ((E/Z) -TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z) -Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer[1][2].

• Product Name Alternative:

  (E/Z) -TG02; (E/Z) -SB1317

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  CDK; FLT3; JAK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/e-z-zotiraciclib.html

• Purity:

  99.96

• Solubility:

  DMSO : 26.5 mg/mL (ultrasonic; warming)

• Smiles:

  CN1CC2=CC(NC3=NC(C4=CC(OCC/C=C/C1)=CC=C4)=CC=N3)=CC=C2

• Molecular Formula:

  C23H24N4O

• Molecular Weight:

  372.46

• Precautions:

  H302

• References & Citations:

  [1]William AD, et al. Discovery of kinase spectrum selective macrocycle (16E) -14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1 (2,6) .1 (8,12) ]heptacosa-1 (25),2 (26),3,5,8 (27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kina|[2]Pasha MK, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6 (1) :33-42.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK2; JAK2

• CAS Number:

  [937270-47-8]